Multiple Sclerosis
ALLOZYNE Announces Completion of Phase IA Trial by AZ01, a Long Lasting Interferon b for Treatment of Relapsing Remitting Multiple Sclerosis
Published in Drug Law Weekly, January 25th, 2011
2011 JAN 25 -- ALLOZYNE, Inc. announced, the completion of its first Phase IA clinical trial in healthy individuals for AZ01, a PEGylated form of human interferon beta-1b which is being developed for the treatment of relapsing remitting multiple sclerosis. The objectives of the Phase IA trial were to assess safety and tolerability profile in addition to defining its pharmacological properties. The results demonstrate that single administrations of AZ01 were well tolerated at all dosage levels tested. In addition, drug serum levels and interferon activity biomarkers were maintained well after administration in the highest dose groups indicating that once a month dosing may be a...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Drug Law Weekly
Source: Drug Law Weekly (2011-01-25)
More Articles from Drug Law Weekly
- Constipation
Adolor Corporation Expands Phase 2 Opioid Induced Constipation Program - Public Health
Aeolus Pharmaceuticals Announces Presentation of AEOL 10150 Data at the HHS 5th Annual Public Health Emergency Medical Countermeasures Enterprise - BARDA Industry Day - Xenografts
Analytical Biochemistry Publishes Results of an Analysis of Two Pharmacodynamic Biomarkers Using the ViBE(TM) Protein Analysis Workstation - Marketing and Licensing Agreements
Anchor Therapeutics Achieves Milestone in GPCR Collaboration - More from this issue of Drug Law Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
